S.Z., O.P, R.G., D.D. G.K, M.H, P.F, C.W.A.L-C.: no relevant disclosures. S.S.: Consulting or advisory role for Janssen, Bristol-Myers Squibb, Legend, Magenta Therapeutics, Sanofi, Pfizer, Takeda, Kite, Abbvie and Regeneron; Research funding from Janssen, Magenta Therapeutics, Allogene Therapeutics, Novartis and Bristol-Myers Squibb; L.S.: Consulting or Advisory role for Janssen Oncology; O.C.P.: Consulting or Advisory role for BMS/Celgene/Juno, Legend Biotech; A.A.: Consulting or Advisory role for BMS, Karyopharm, Research funding from Abbvie, Adaptive biotechnologies; J.A.D.: consultancy for Janssen; H.H.; Consulting or Advisory role for Sanofi, BMS/Celgene, Janssen; speaker’s bureau: Janssen, Karyopharm, Amgen; D.S.: Consulting or Advisory role for Sanofi, GSK, BMS/Celgene, Janssen, Abbvie, Pfizer, Arcellx, BiolineRx, Astrazeneca, research funding from Pfizer; L.D.A. Jr: consulting or advisory board role for Janssen, Celgene, Bristol Myers Squibb, Amgen, GlaxoSmithKline, AbbVie, BeiGene, Cellectar, Sanofi, Karyopharm, Oncopeptides, and Prothena. J.M: Honoraria: Kite, a Gilead company, AlloVir, Magenta Therapeutics, Nektar, Sana Biotechnology; Consulting or Advisory Role: Kite, a Gilead company, Juno Therapeutics, AlloVir, Magenta Therapeutics, EcoR1 Capital, CRISPR therapeutics; Speakers’ Bureau: Kite/Gilead; Research Funding: Novartis (Inst), Fresenius Biotech (Inst), Astellas Pharma (Inst), Bellicum Pharmaceuticals (Inst), Novartis (Inst), Gamida Cell (Inst), Pluristem Therapeutics (Inst), Kite, a Gilead company (Inst), AlloVir (Inst); Travel, Accommodations, Expenses: Kite, a Gilead company; A.R.: consultant for Sanofi, BMS, Janssen, and Adaptive. C.R. is a consultant for Janssen, BMS, Takeda, Sanofi, and Artiva; C.L.F: horonoraria and consulting- Bristol Myers Squibb, Seattle Genetics, Celgene, AbbVie, Sanofi, Incyte, Amgen, ONK Therapeutics & Janssen; and research funding from Bristol Myers Squibb, Janssen, and Roche/Genentech; F.L.L.: Scientific Advisory Role/Consulting Fees: A2, Allogene, Amgen, Bluebird Bio, BMS, Calibr, Caribou, Cowen, EcoR1, Gerson Lehrman Group (GLG), Iovance, Kite Pharma, Janssen, Legend Biotech, Novartis, Sana, Umoja, Pfizer; Data Safety Monitoring Board: Data and Safety Monitoring Board for the NCI Safety Oversight CAR T-cell Therapies Committee. Research Contracts or Grants to my Institution for Service: Kite Pharma (Institutional), Allogene (Institutional), CERo Therapeutics (Institutional), Novartis (Institutional), BlueBird Bio (Institutional), 2SeventyBio (Institutional), BMS (Institutional), National Cancer Institute (R01CA244328 MPI: Locke; P30CA076292 PI: Cleveland), Leukemia and Lymphoma Society Scholar in Clinical Research (PI: Locke); Patents, Royalties, Other Intellectual Property: Several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy; Education or Editorial Activity: Aptitude Health, ASH, BioPharma Communications CARE Education, Clinical Care Options Oncology, Imedex, Society for Immunotherapy of Cancer S.R.: Honoraria: BMs, Jansssen; Consulting or Advisory Role: Genentech; Research Funding: Janssen, C4 therapeutics, Gracell, Heidelberg Pharma; J.K.: Consulting or Advisory Role: Janssen Oncology; Honoraria: GPCR therapeutics; Y.L.: Consulting or Advisory role: Kite/Gilead, BMS, Vineti, Janssen Oncology, Pfizer; Sanofi, NexImmune, Caribou biosciences, Regeneron, Genentech, Fosun Kite, Chimeric Therapeutics, Adicet Bio, Nektar; Research Funding: Janssen Oncoloyg, BMS, Merck, Takeda, Boston Scientific, Kite/Gilead, Bluebird Bio; K.K.P.: Consulting or Advisory Role: Celgene, BMS, Janssen, Pfizer, Arcellx, Karyopharm Therapeutics, Merck, Cellectis, Caribou Biosciences, Takeda, Abbvie, Travel, Accomodation, Expenses: BMS; Research funding: Celgene/BMs, Takeda, Janssen, Cellectis, Nektar, Abbvie/Genentech, Precision Biosciences, Allogene Therapeutics; S.K.: Consulting or Advisory Role: Takeda, Janssen Oncology, Genentech/Rocher, Abbvie, BMS/Celgene, Pfizer, Regeneron, Sanofi, K36 Therapeutics; travel, accomodation and expenses: Abbvie, pfizer; Research funding: Takeda, Abbvie, Novartis, Sanofi, Janssen Oncology, MedImmune, Roche/Genentech, CARsgen Therapeutics, Allogene Therapeutics, GSK, Regeneron, BMS/Celgene; D.K.H.: Research funding from Bristol-Myers Squibb, Karyopharm, and Adaptive Biotech; Consulting or advisory role for Bristol-Myers Squibb, Janssen, Pfizer, and Karyopharm. D.K.H is also supported by the Pentecost Family Myeloma Research Center.

S.Z., O.P, R.G., D.D. G.K, M.H, P.F, C.W.A.L-C.: no relevant disclosures. S.S.: Consulting or advisory role for Janssen, Bristol-Myers Squibb, Legend, Magenta Therapeutics, Sanofi, Pfizer, Takeda, Kite, Abbvie and Regeneron; Research funding from Janssen, Magenta Therapeutics, Allogene Therapeutics, Novartis and Bristol-Myers Squibb; L.S.: Consulting or Advisory role for Janssen Oncology; O.C.P.: Consulting or Advisory role for BMS/Celgene/Juno, Legend Biotech; A.A.: Consulting or Advisory role for BMS, Karyopharm, Research funding from Abbvie, Adaptive biotechnologies; J.A.D.: consultancy for Janssen; H.H.; Consulting or Advisory role for Sanofi, BMS/Celgene, Janssen; speaker’s bureau: Janssen, Karyopharm, Amgen; D.S.: Consulting or Advisory role for Sanofi, GSK, BMS/Celgene, Janssen, Abbvie, Pfizer, Arcellx, BiolineRx, Astrazeneca, research funding from Pfizer; L.D.A. Jr: consulting or advisory board role for Janssen, Celgene, Bristol Myers Squibb, Amgen, GlaxoSmithKline, AbbVie, BeiGene, Cellectar, Sanofi, Karyopharm, Oncopeptides, and Prothena. J.M: Honoraria: Kite, a Gilead company, AlloVir, Magenta Therapeutics, Nektar, Sana Biotechnology; Consulting or Advisory Role: Kite, a Gilead company, Juno Therapeutics, AlloVir, Magenta Therapeutics, EcoR1 Capital, CRISPR therapeutics; Speakers’ Bureau: Kite/Gilead; Research Funding: Novartis (Inst), Fresenius Biotech (Inst), Astellas Pharma (Inst), Bellicum Pharmaceuticals (Inst), Novartis (Inst), Gamida Cell (Inst), Pluristem Therapeutics (Inst), Kite, a Gilead company (Inst), AlloVir (Inst); Travel, Accommodations, Expenses: Kite, a Gilead company; A.R.: consultant for Sanofi, BMS, Janssen, and Adaptive. C.R. is a consultant for Janssen, BMS, Takeda, Sanofi, and Artiva; C.L.F: honoraria and consulting- Bristol Myers Squibb, Seattle Genetics, Celgene, AbbVie, Sanofi, Incyte, Amgen, ONK Therapeutics & Janssen; and research funding from Bristol Myers Squibb, Janssen, and Roche/Genentech; F.L.L.: Scientific Advisory Role/Consulting Fees: A2, Allogene, Amgen, Bluebird Bio, BMS, Calibr, Caribou, Cowen, EcoR1, Gerson Lehrman Group (GLG), Iovance, Kite Pharma, Janssen, Legend Biotech, Novartis, Sana, Umoja, Pfizer; Data Safety Monitoring Board: Data and Safety Monitoring Board for the NCI Safety Oversight CAR T-cell Therapies Committee. Research Contracts or Grants to my Institution for Service: Kite Pharma (Institutional), Allogene (Institutional), CERo Therapeutics (Institutional), Novartis (Institutional), BlueBird Bio (Institutional), 2SeventyBio (Institutional), BMS (Institutional), National Cancer Institute (R01CA244328 MPI: Locke; P30CA076292 PI: Cleveland), Leukemia and Lymphoma Society Scholar in Clinical Research (PI: Locke); Patents, Royalties, Other Intellectual Property: Several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy; Education or Editorial Activity: Aptitude Health, ASH, BioPharma Communications CARE Education, Clinical Care Options Oncology, Imedex, Society for Immunotherapy of Cancer S.R.: Honoraria: BMs, Jansssen; Consulting or Advisory Role: Genentech; Research Funding: Janssen, C4 therapeutics, Gracell, Heidelberg Pharma; J.K.: Consulting or Advisory Role: Janssen Oncology; Honoraria: GPCR therapeutics; Y.L.: Consulting or Advisory role: Kite/Gilead, BMS, Vineti, Janssen Oncology, Pfizer; Sanofi, NexImmune, Caribou biosciences, Regeneron, Genentech, Fosun Kite, Chimeric Therapeutics, Adicet Bio, Nektar; Research Funding: Janssen Oncoloyg, BMS, Merck, Takeda, Boston Scientific, Kite/Gilead, Bluebird Bio; K.K.P.: Consulting or Advisory Role: Celgene, BMS, Janssen, Pfizer, Arcellx, Karyopharm Therapeutics, Merck, Cellectis, Caribou Biosciences, Takeda, Abbvie, Travel, Accomodation, Expenses: BMS; Research funding: Celgene/BMs, Takeda, Janssen, Cellectis, Nektar, Abbvie/Genentech, Precision Biosciences, Allogene Therapeutics; S.K.: Consulting or Advisory Role: Takeda, Janssen Oncology, Genentech/Rocher, Abbvie, BMS/Celgene, Pfizer, Regeneron, Sanofi, K36 Therapeutics; travel, accomodation and expenses: Abbvie, pfizer; Research funding: Takeda, Abbvie, Novartis, Sanofi, Janssen Oncology, MedImmune, Roche/Genentech, CARsgen Therapeutics, Allogene Therapeutics, GSK, Regeneron, BMS/Celgene; D.K.H.: Research funding from Bristol-Myers Squibb, Karyopharm, and Adaptive Biotech; Consulting or advisory role for Bristol-Myers Squibb, Janssen, Pfizer, and Karyopharm. D.K.H is also supported by the Pentecost Family Myeloma Research Center.